Worth reading
45Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
100000000
¥Wording
Conditional
How definitive the wording is.Agreements reached under this partnership
Business alliance4263SUSMED,Inc.
Alliance partnerASKA Pharmaceutical Co., Ltd.
Details of the alliance
- 1
産婦人科領域における治療用アプリの共同研究開発及び販売
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
About the partner
LocationMinato-ku, Tokyo
Impact on Business Performance
今回受領するマイルストン報酬は、2026年6月期の事業収益として計上する見込みです。
| Item | Details |
|---|---|
| Name of alliance partner | ASKA Pharmaceutical Co., Ltd. |
| Alliance partner's location | Minato-ku, Tokyo |
| Type of alliance | Business alliance |
| Details of the alliance | 産婦人科領域における治療用アプリの共同研究開発及び販売 |
| Impact on Business Performance | 今回受領するマイルストン報酬は、2026年6月期の事業収益として計上する見込みです。 |
Items this document does not state (18)
Alliance partner's business activitiesAlliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionContract DateAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.探索的試験で有効な結果が確認され、両社が次の開発段階に進むことに合意したため。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.